Anagliptin and sitagliptin as add‐ons to metformin for patients with type 2 diabetes: a 24‐week, multicentre, randomized, double‐blind, active‐controlled, phase III clinical trial with a 28‐week extension

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 5, 2015-05 ,pp. : 511-515

John Wiley & Sons Inc

Access to resources Recommend Favorite

Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double‐blind, active‐controlled, parallel group, multinational clinical trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 2, 2015-02 ,pp. : 136-144

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double‐blind, active‐controlled, phase 3 trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 590-598

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16‐week, randomized, double‐blind, placebo‐controlled phase III trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 3, 2015-03 ,pp. : 309-312

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double‐blind, parallel‐group, comparative study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 12, 2015-12 ,pp. : 1198-1201

John Wiley & Sons Inc

Access to resources Recommend Favorite